In a nutshell This study compared the survival rates for older patients with early-stage breast cancer (BC) receiving hormone therapy (HT), radiation (RT), both or none after breast-conserving surgery (BCS). The data showed that RT and HT in combination and RT alone may lead to higher survival expectancy than HT alone. Some...
Read More
In a nutshell This trial evaluated strategies to improve diarrhea as a side effect of neratinib (Nerlynx) treatment in patients with HER2-positive breast cancer (BC). The authors showed that slowly increasing the doses of neratinib or taking anti-diarrhea medication can improve this side effect. Some background Neratinib (Nerlynx) is a targeted...
Read More
In a nutshell The study evaluated long-term outcomes of combining hypofractionated intensity-modulated radiation therapy (H-IMRT) with prone-positioning in patients after conservation surgery for breast cancer. The authors found that this combination safely controlled cancer locally without affecting regional lymph nodes. Some background Adjuvant...
Read More
In a nutshell The study evaluated the link between statin (cholesterol-lowering drugs) use and risks of breast cancer (BC) relapse under adjuvant aromatase inhibitors (AI) therapy in women after their menopause. The main finding was that statin use was related with lower risks of BC relapse in such patients. Some background Women with...
Read More
In a nutshell This study examined the effectiveness of hormonal therapy in premenopausal women with hormone receptor-positive early breast cancer with or without other treatments. The authors concluded that patients who received hormonal therapy had a higher chance of survival and without a return of cancer. Some background The hormone...
Read MoreIn a nutshell This trial aims to find out what dose of radiation therapy is effective in the shortest time period for women with newly diagnosed breast cancer, or ductal carcinoma in-situ (DCIS). The main outcome that will be measured is if patients experience any side effects. The study is taking place in New Jersey and New York, the United States. The...
Read More
In a nutshell This study reviewed early breast cancer (EBC) treatment guidelines. Some background Breast cancer (BC) is a common and treatable form of cancer. Understanding treatment options is important to improve patient care. Treatment options include surgery and radiotherapy (RT). Adjuvant systemic treatment (AST) is a non-surgical option. AST...
Read More
In a nutshell This study investigated the safety and effectiveness of intraoperative radiotherapy (IORT; radiotherapy during surgery) in early breast cancer (BC). They found that tumor recurrence was low after IORT. Some background Early breast cancer (BC) can be treated using different approaches. Most patients undergo breast-conserving therapy...
Read More
In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...
Read More
In a nutshell This study wanted to find out if adding the medication denosumab (Prolia, Xgeva) to cancer treatment for women with breast cancer reduces the risk of bone fractures. The study found that the patients treated with denosumab survived better, but there was no significant difference in the number of bone fractures. Some background Breast...
Read MoreIn a nutshell This study evaluated the side effects associated with intensity-modulated radiation therapy (IMRT) for advanced breast cancer. This study found that most side effects were mild and did not lower quality of life for patients. Some background Radiotherapy is often performed in breast cancer patients after surgery. Previous studies have...
Read MoreIn a nutshell This study will examine how safe and effective the medication atezolizumab (Tecentriq) is in combination with other anti-cancer medicines for treating early stage HER2+ breast cancer. The main outcome that will be measured is how many patients completely respond to treatment, with no trace of the cancer remaining. The details...
Read More
